Literature DB >> 20133281

Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation.

Ioannis Petrakis1, Kostas Stylianou, Vasiliki Mavroeidi, Eleftheria Vardaki, Spyridon Stratigis, Stavros Stratakis, Irene Xylouri, Constantinos Perakis, Constantina Petraki, Lydia Nakopoulou, Eugene Daphnis.   

Abstract

Light-chain deposition disease (LCDD) is caused by an underlying clonal plasma cell dyscrasia in which monoclonal immunoglobulin light chains (LCs) are deposited in tissues, resulting in varying degrees of organ dysfunction. Autologous stem cell transplantation (ASCT) has been reported to stabilize renal function in patients with LCDD, but currently, no evidence of histopathologic resolution of LC deposition after ASCT exists. We present a patient, with severe renal dysfunction due to LCDD, who was treated with high-dose melphalan and ASCT that resulted in a significant and extended period of improved renal function. Four years after the initial improvement, the patient developed nephrotic range proteinuria, without any evidence of relapse of the plasma cell dyscrasia. At that time, a repeat renal biopsy showed complete resolution of LC depositions and development of extensive glomerulosclerosis, thus explaining proteinuria. To the best of our knowledge, this is the first report of a biopsy-proven resolution of renal LCDD following ASCT. A timely application of ASCT should be considered in LCDD to prevent deterioration of renal function in the long run.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20133281     DOI: 10.1093/ndt/gfq023

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

1.  Long-term reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous stem cell transplantation.

Authors:  Tomás J González-López; Lourdes Vázquez; Teresa Flores; Jesus Fernando San Miguel; Ramon García-Sanz
Journal:  Clin Pract       Date:  2011-11-23

2.  Five Sequential Evaluations of Renal Histology in a Patient with Light Chain Deposition Disease.

Authors:  Toshiharu Ueno; Koichi Kikuchi; Ryo Hazue; Koki Mise; Keiichi Sumida; Noriko Hayami; Tatsuya Suwabe; Junichi Hoshino; Naoki Sawa; Kenji Arizono; Shigeko Hara; Kenmei Takaichi; Takeshi Fujii; Kenichi Ohashi; Yoshifumi Ubara
Journal:  Intern Med       Date:  2016-10-15       Impact factor: 1.271

3.  Light chain deposition disease involving kidney and liver in a patient with IgD myeloma.

Authors:  Takafumi Tsushima; Tomo Suzuki; Toshiki Terao; Daisuke Miura; Kentaro Narita; Masami Takeuchi; Akira Shimuzu; Kosei Matsue
Journal:  BMC Nephrol       Date:  2021-01-23       Impact factor: 2.388

4.  Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone.

Authors:  Di Wang; Yan Wang; Shiren Sun
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

5.  Light Chain Deposition Disease Diagnosed Using Computed Tomography-Guided Kidney Biopsy.

Authors:  Yoshinosuke Shimamura; Yayoi Ogawa; Hideki Takizawa; Toshiaki Hayashi; Yasuo Sakurai
Journal:  Cureus       Date:  2021-05-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.